Genprex, Inc., a biotechnology company operating within the Health Care sector, has been making strides in the field of immunogene therapies for cancer treatment. As of September 8, 2025, the company’s stock is trading at a close price of $0.209 on the Nasdaq exchange, reflecting a significant decline from its 52-week high of $3.97, recorded on October 21, 2024. The 52-week low was observed at $0.14 on August 20, 2025. Despite these fluctuations, Genprex maintains a market capitalization of approximately $6,994,557 USD.
Founded with a focus on pioneering immunogene therapies, Genprex has positioned itself as a key player in the biotechnology industry. The company’s primary mission is to discover and develop innovative therapies aimed at treating cancer, leveraging cutting-edge gene therapy techniques. In addition to its core focus, Genprex extends its expertise to clinical research and consulting services, providing comprehensive support to its clientele within the United States.
Since its Initial Public Offering (IPO) on March 29, 2018, Genprex has been listed on the Nasdaq stock exchange, allowing it to access broader capital markets and enhance its research and development capabilities. The company’s strategic initiatives are centered around advancing its therapeutic pipeline and expanding its service offerings to meet the evolving needs of the healthcare sector.
Genprex’s commitment to innovation is evident in its ongoing efforts to refine and enhance its immunogene therapy platforms. By focusing on the development of targeted therapies, the company aims to improve patient outcomes and contribute to the broader fight against cancer. As it continues to navigate the challenges and opportunities within the biotechnology landscape, Genprex remains dedicated to its mission of transforming cancer treatment through groundbreaking scientific advancements.